TRE, Low-Carb Diets, and Thyroid Markers: What a Trial Found

Time-restricted eating may help people with metabolic syndrome lose weight and reduce visceral fat. Whether it directly improves the heart or thyroid is a much less settled question. A 2024 secondary analysis reported lower enzyme levels and a shift in thyroid hormones after three months of time-restricted eating, a low-carbohydrate diet, or both. Yet none of the three strategies outperformed the others on any cardiac-enzyme or thyroid endpoint.

That result changes the interpretation. The trial supports dietary weight loss for metabolic syndrome. It does not show that an eight-hour eating window has a special effect on myocardial health or thyroid function.

What the 12-week trial actually tested

The analysis drew on a 12-week, open-label randomized trial in Xi'an, China involving 169 adults with metabolic syndrome. Participants followed a low-carbohydrate diet, 16:8 time-restricted eating with an eight-hour eating window, or both strategies together. The parent trial focused on body weight and visceral fat, not cardiac enzymes or thyroid hormones.

All three approaches produced roughly 5% to 7% weight loss and reduced visceral fat over three months in the 2022 parent randomized trial. Those are meaningful outcomes for metabolic syndrome, a condition linked with excess abdominal fat, elevated glucose, dyslipidemia, and high blood pressure.

The later 2024 secondary analysis by Zheng et al. measured creatine kinase (CK), CK-MB, lactate dehydrogenase (LDH), hydroxybutyrate dehydrogenase (HBDH), free T3 (FT3), free T4 (FT4), thyroid-stimulating hormone (TSH), and two thyroid antibodies. Within at least one diet group, CK, LDH, HBDH, and FT3 fell, while FT4 rose.

The result that deserves the most attention is less glamorous: the investigators found no statistically significant between-group differences for any myocardial-enzyme or thyroid endpoint. Low-carb alone, time-restricted eating alone, and the combined plan produced statistically indistinguishable changes over 12 weeks.

The shared effect was probably weight loss

When three dietary plans lead to similar weight loss and similar biomarker changes, the common feature is the leading explanation. In this trial, that feature was an energy deficit accompanied by reduced visceral fat and roughly 5% to 7% weight loss—not a detectable advantage from meal timing, carbohydrate restriction, or combining the two.

A separate secondary analysis from the same trial reached a similar comparative result for appetite and psychosocial outcomes: none of the dietary arms differed significantly from the others. The companion 2024 analysis does not prove that every benefit came from weight loss, but it makes a strategy-specific claim harder to support.

Broader evidence points in the same direction. A 2025 systematic review and meta-analysis found that intermittent-fasting approaches in metabolic syndrome improved weight and metabolic measures. A 2022 meta-analysis of randomized trials found improvements in lipids, glucose, and blood pressure. Neither review established a specific effect on myocardial enzymes or thyroid hormone fractions.

Time-restricted eating can still have features beyond calorie counting. A 2024 meta-analysis of time-restricted eating found better glycemic control when food intake aligned with circadian timing. That is a plausible benefit for glucose handling. It is not evidence that time restriction repairs heart muscle or upgrades thyroid output.

"Myocardial enzymes" are a misleading label here

The cardiac claim rests on surrogate biomarkers, not heart attacks, heart failure, imaging, exercise capacity, troponin, or other patient-centered cardiovascular outcomes. CK and LDH are especially poor stand-ins for direct myocardial benefit.

Most circulating CK in healthy adults is CK-MM, the skeletal-muscle isoform. CK-MB has greater cardiac relevance, but clinicians generally interpret it in context, including its fraction of total CK. LDH is distributed widely across skeletal muscle, liver, kidneys, and red blood cells. HBDH has some cardiac enrichment through LDH-1, but it also lacks specificity.

The study did not report CK-MB as a fraction of total CK or perform LDH isoenzyme profiling. A fall in CK or LDH therefore cannot identify the heart as the source of the change. In people with obesity and metabolic disease, skeletal-muscle turnover and impaired anabolic responses can contribute to these circulating signals; a 2025 analysis by Nilsson et al. documents impaired muscle anabolic responses in obesity and metabolic disease. Weight loss could plausibly reduce the overall skeletal-muscle metabolic burden. The trial cannot separate that explanation from direct cardiac effects.

If CK or LDH falls during a successful diet, treat it as an ambiguous laboratory change, not as proof that your eating window improved cardiac function.

The thyroid pattern looks like energy conservation

The thyroid results need the same restraint. FT3 fell and FT4 rose across the dietary interventions, while TSH remained stable. The authors described this as improved thyroid function. Established endocrine physiology offers a more conventional explanation: sustained energy restriction can reduce conversion of T4 into active T3, lowering T3 availability and conserving energy.

This adaptive low-T3 pattern differs from classic primary hypothyroidism. In primary hypothyroidism, TSH generally rises because the pituitary senses inadequate thyroid hormone activity. During an energy-deficit response, TSH may remain stable or fall while FT3 decreases and FT4 stays normal or rises. The body is adjusting energy expenditure; it is not necessarily producing a healthier thyroid state.

The study did not measure reverse T3, which would have helped test the proposed shift in peripheral thyroid-hormone conversion. It also lasted only three months. The fasting and metabolic-syndrome reviews above support the broader reality of metabolic adaptation during weight-loss interventions, but they did not test thyroid fractionation or establish that the observed pattern improves thyroid health.

An unexplained antibody signal deserves follow-up, not conclusions

TgAb and TMAb, two thyroid autoantibodies, increased only in the time-restricted-eating group of 57 participants. This finding is hypothesis-generating. The study was a secondary analysis, its intervention lasted three months, and the available evidence does not provide corroborating fasting trials showing the same antibody pattern.

People with Hashimoto's thyroiditis, Graves' disease in remission, or known thyroid-antibody positivity should not assume that time-restricted eating will worsen their condition. They also should not dismiss the result as meaningless. A clinician can decide whether baseline and follow-up TSH, FT4, FT3, and antibody testing make sense for an individual situation.

What this means for a real-world eating plan

Time-restricted eating and low-carbohydrate diets remain reasonable tools for people who can sustain them and who want to lose weight or reduce visceral fat. The parent trial and the wider metabolic-syndrome literature support those uses. A 2024 meta-analysis of low-carbohydrate diets also found that calorie restriction substantially mediates metabolic and inflammatory changes, which fits the trial's lack of separation among diet arms.

Choose the approach you can follow safely and consistently, ideally with enough protein, fiber, micronutrients, and medical oversight when medications or diabetes are involved. Do not choose time-restricted eating because a secondary analysis suggested direct myocardial protection or thyroid enhancement. The study did not test either claim with specific cardiac markers, clinical outcomes, or a design powered for these endpoints.

The useful finding is simple: dietary strategies that produced similar short-term weight loss also produced similar biomarker shifts. The cardiac and thyroid interpretations remain hypotheses until primary trials measure cardiac-specific biomarkers, reverse T3, long-term thyroid antibodies, and clinical outcomes.